Corbus Pharmaceuticals Holdings (CRBP) said Tuesday that CRB-701 has received fast track designation from the US Food and Drug Administration for the treatment of relapsed or refractory metastatic cervical cancer.
The company said the designation aims to facilitate the development and hasten the review of drugs that have the "potential to fill an unmet medical need."
Corbus said it recently completed enrollment of the dose escalation part of its phase 1 clinical trial of CRB-701 and expects to release the first data from the dose escalation clinical study in Q1.
Corbus shares were up 5.9% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。